Health care stocks were leaning lower premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was down 0.7% and the iShares Biotechnology ETF (IBB) was inactive.
Marinus Pharmaceuticals (MRNS) soared 43% after it said it signed a deal under which Immedica Pharma will acquire all of its issued and outstanding shares for $0.55 a share.
Axsome Therapeutics (AXSM) said Monday it has met the primary endpoint in its ACCORD-2 phase 3 trial of AXS-05, which is intended for Alzheimer's disease agitation, but failed to achieve statistical significance for its primary endpoint in another trial. Axsome shares slid 7.1%.
Precigen (PGEN) said Monday it has completed a rolling biologics license application submission to the US Food and Drug Administration for PRGN-2012, a treatment for recurrent respiratory papillomatosis in adults. Precigen shares rose 12.8%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。